| 05th week of 2016 patent applcation highlights part 25 |
| Patent application number | Title | Published |
|---|
| 20160031953 | Recombinantly Expressed Plasmodium CelTOS Antigen and Methods of Use Thereof - A synthetic nucleotide, which transcribes as the cell-traversal protein for ookinetes and sporozoites (CelTOS) antigen of Malaria | 2016-02-04 |
| 20160031954 | WATER BUFFALO DERIVED DIMERIC PEPTIDE CONTAINING PROLINE FOR ANTIBIOTIC THERAPIES - The present disclosure relates to antimicrobial agents and methods of using such agents. The disclosure includes antimicrobial agents having broad spectrum antimicrobial activity, nucleic acids and amino acid sequences encoding such antimicrobial agents, as well as methods of using the antimicrobial agents. The antimicrobial agents of the disclosure may be used to reduce survival of a microbe, as an antimicrobial therapeutic, in microbial treatment protocols, and in research, as well as other uses related to reducing microbe survival. In addition, the disclosure also includes compositions, as well as articles of manufacture, that comprise a broad spectrum antimicrobial agent. | 2016-02-04 |
| 20160031955 | Methods for Treating Mitochondrial Disorders and Neurodegenerative Disorders - The present invention relates to a recombinant inner mitochondrial membrane polypeptide, and its use in methods for treating mitochondrial disorders. | 2016-02-04 |
| 20160031956 | Compositions Comprising Hypoxia Inducible Factor-1 Alpha and Methods of Using the Same - Disclosed herein is a therapeutic comprising hypoxia inducible factor-1 alpha (HIF-1α). Also disclosed herein is a method for treating hypoxia or ischemia in a subject in need thereof. The method may comprise administering the vaccine to the subject in need thereof. | 2016-02-04 |
| 20160031957 | INHIBITORS OF THE LINEAR UBIQUITIN CHAIN ASSEMBLY COMPLEX (LUBAC) AND RELATED METHODS - The invention relates to peptide inhibitors of linear ubiquitin chain assembly complex (LUBAC) and to methods of treating diseases including activated B-cell like diffuse large B cell lymphboma (ABC DLBCL) and autoimmune or inflammatory disorders. | 2016-02-04 |
| 20160031958 | METHODS AND COMPOSITIONS USEFUL IN MANIPULATING THE STABILITY OF RE1 SILENCING TRANSCRIPTION FACTOR - Disclosed are methods of screening for compounds that promote REST degradation by inhibiting the activity of the CDTSP1 phosphorylase including fluorescent and antibody based screens. Also disclosed are peptides that promote REST stabilization as well as antibodies that recognize REST phosphorylated at serine 861 and serine 864. | 2016-02-04 |
| 20160031959 | BH4 STABILIZED PEPTIDES AND USES THEREOF - Provided herein are polypeptides containing stabilized BH4 domains of BCL-2 family proteins that are capable of binding and/or inactivating and/or modulating BAX protein, and/or its close homologues BAK and BOK, and/or other physiological BH4 targets. Also provided are compositions containing these polypeptides and methods of treating cytotoxic diseases that include administering to a subject one of the polypeptides. | 2016-02-04 |
| 20160031960 | COMPOSITIONS AND METHODS OF USE FOR TREATING METABOLIC DISORDERS - Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided. | 2016-02-04 |
| 20160031961 | METHODS AND COMPOSITIONS USING KLOTO-FGF FUSION POLYPEPTIDES - The present invention is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The Klotho fusion polypeptides of the invention include at least a Klotho protein or an active fragment thereof. In one embodiment, the fusion polypeptide comprises a Klotho polypeptide, a FGF (such as FGF23) and (optionally) a modified Fc fragment. The Fc fragment can, for example, have decreased binding to Fc-gamma-receptor and increased serum half-life. The Klotho fusion proteins are useful in the treatment and prevention of a variety of age-related conditions and metabolic disorders. In another embodiment, the fusion polypeptide comprises a FGF (such as FGF23) and a modified Fc fragment. | 2016-02-04 |
| 20160031962 | SOLID PHASE PEPTIDE SYNTHESIS OF INSULIN USING SIDE CHAIN ACHORED LYSINE - The present application discloses the preparation of peptides, including insulin and insulin derivatives, using efficient methods for solid-phase and solution phase peptide synthesis. | 2016-02-04 |
| 20160031963 | Targeted Therapeutic Lysosomal Enzyme Fusion Proteins and Uses Thereof - The present invention relates in general to therapeutic fusion proteins useful to treat lysosomal storage diseases and methods for treating such diseases. Exemplary therapeutic fusion proteins comprise a lysosomal enzyme, a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. Also provided are compositions and methods for treating Mucopolysaccharidosis Type IIIB (Sanfilippo B Syndrome), comprising a targeted therapeutic fusion protein comprising alpha-N-acetylglucosaminidase (Naglu), a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. | 2016-02-04 |
| 20160031964 | Targeted Therapeutic Lysosomal Enzyme Fusion Proteins and Uses Thereof - The present invention relates in general to therapeutic fusion proteins useful to treat lysosomal storage diseases and methods for treating such diseases. Exemplary therapeutic fusion proteins comprise a lysosomal enzyme, a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. Also provided are compositions and methods for treating Mucopolysaccharidosis Type IIIB (Sanfilippo B Syndrome), comprising a targeted therapeutic fusion protein comprising alpha-N-acetylglucosaminidase (Naglu), a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. | 2016-02-04 |
| 20160031965 | Targeted Therapeutic Lysosomal Enzyme Fusion Proteins and Uses Thereof - The present invention relates in general to therapeutic fusion proteins useful to treat lysosomal storage diseases and methods for treating such diseases. Exemplary therapeutic fusion proteins comprise a lysosomal enzyme, a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. Also provided are compositions and methods for treating Mucopolysaccharidosis Type IIIB (Sanfilippo B Syndrome), comprising a targeted therapeutic fusion protein comprising alpha-N-acetylglucosaminidase (Naglu), a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. | 2016-02-04 |
| 20160031966 | MUTANT PROTEINS AND METHODS FOR THEIR PRODUCTION - The present invention relates to mutant transmembrane proteins which have increased conformational stability when compared to their parent protein, methods of selection and production. In particular the invention relates to mutant transmembrane proteins which are mutated in or in the proximity of the transmembrane alpha helices or in a kinked region or in an alpha-helix adjacent to a kink. The mutant transmembrane proteins have use in crystallisation studies and also in screening to identify compounds for use in drug discovery and therapy. | 2016-02-04 |
| 20160031967 | POLYPEPTIDES - The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EX | 2016-02-04 |
| 20160031968 | VARIANT FACTOR VIII POLYPEPTIDES AND METHODS OF THEIR PRODUCTION AND USE - This disclosure relates to variant Factor VIII polypeptides comprising an amino acid substitution at one or more positions within one or both of the thrombin cleavage site and the activation loop. In certain embodiments, the variant Factor VIII polypeptide comprises one or more amino acid substitutions within both the thrombin cleavage site and the activation loop. In further embodiments, the variant factor VIII polypeptide further comprises one or more amino acid substitutions within the A1-A2 domain interface and the A2-A3 domain interface. The present disclosure further relates to methods of producing and/or using such variant Factor VIII polypeptides; nucleic acids encoding the polypeptides; vectors and/or recombinant cells, tissues, or organisms containing such nucleic acids; and kits and pharmaceutical compositions containing such polypeptides and/or nucleic acids. | 2016-02-04 |
| 20160031969 | VARIANTS OF TISSUE INHIBITOR OF METALLOPROTEINASE TYPE THREE (TIMP-3), COMPOSITIONS AND METHODS - There are disclosed TIMP-3 muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them. | 2016-02-04 |
| 20160031970 | FERMENTATION PROCESS FOR ANTIBODY PRODUCTION - A feedback control mechanism for a fermentation of yeast cells to make recombinant proteins uses a respiratory quotient measurement which adjusts the levels of oxygenation and/or fermentable sugar feed. The feedback control mechanism permits well controlled cultures that produce good amounts of product while avoiding toxic accumulation of ethanol. Additionally, recombinant proteins so produced have excellent qualitative properties, such as excellent homogeneity and proper inter-subunit assembly. | 2016-02-04 |
| 20160031971 | Methods and compositions with a recombinant neutralizing binding protein for treating toxin exposure - Methods, compositions and kits are provided for treating a subject exposed to or at risk for exposure to a disease agent using a pharmaceutical composition including at least one recombinant binding protein or a source of expression of the binding protein, wherein the binding protein neutralizes at least one or a plurality of disease agents that are toxins, for example at least one of a ricin toxin, a Shiga toxin, or an anthrax toxin. | 2016-02-04 |
| 20160031972 | EPITOPE OF RSV FUSION PROTEIN AND ANTIBODY RECOGNIZING THE SAME - The present invention relates to an epitope peptide (or a variant thereof) which can be used in the prevention of respiratory syncytial virus (RSV) infection, a recombinant protein comprising the epitope peptide (or a variant thereof) and a carrier protein, and uses of the epitope peptide (or a variant thereof) and the recombinant protein. The present invention also relates to an antibody against the epitope peptide, a cell line for generating the antibody, and uses thereof. Furthermore, the present invention also relates to a vaccine or a pharmaceutical composition comprising the recombinant protein or the antibody according to the invention, for preventing one or more symptoms associated with RSV infection. | 2016-02-04 |
| 20160031973 | TREATMENT OF STAPHYLOCOCCAL DISORDERS - Materials and methods are provided for treatment and/or prevention of Staphylococcal diseases and disorders such as infection and dermal inflammation. | 2016-02-04 |
| 20160031974 | ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN 0X40 - The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules. | 2016-02-04 |
| 20160031975 | Compositions and Methods for Antibodies Targeting Complement Protein C5 - The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof. | 2016-02-04 |
| 20160031976 | TAU IMMUNOTHERAPY - The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration. | 2016-02-04 |
| 20160031977 | METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF CONFORMATION-SPECIFIC ANTIBODIES - The present invention features methods and compositions for the generation and use of conformation-specific anti-bodies or fragments thereof. | 2016-02-04 |
| 20160031978 | COMPOSITION AND METHOD FOR PREVENTING OR TREATING A TAUOPATHY - The present invention is a composition and method for the prevention and treatment of a tauopathy. The composition of the invention includes N-terminal amino acid residues of the tau protein, which have been identified as being involved in toxic activation of a PP1/GSK3 signaling cascade and inhibition of fast axonal transport in human tauopathies. | 2016-02-04 |
| 20160031979 | METHODS FOR TREATING OSTEOGENESIS IMPERFECTA - The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of a binding agent that binds to transforming growth factor beta (TGFβ). | 2016-02-04 |
| 20160031980 | COMPOSITIONS AND METHODS FOR GROWTH FACTOR MODULATION - Provided herein are proteins, antibodies, assays and methods useful for modulating growth factor levels and/or activities. In some embodiments, such growth factors are members of the TGF-β superfamily of proteins. | 2016-02-04 |
| 20160031981 | METHODS AND COMPOSITIONS FOR DELIVERING MRNA CODED ANTIBODIES - The present invention provides, among other things, methods and compositions for delivering an antibody in vivo by administering to a subject in need thereof one or more mRNAs encoding a heavy chain and a light chain of an antibody, and wherein the antibody is expressed systemically in the subject. In some embodiments, the one or more mRNAs comprise a first mRNA encoding the heavy chain and a second mRNA encoding the light chain of the antibody. | 2016-02-04 |
| 20160031982 | Stable Aqueous Formulations of Adalimumab - The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same. | 2016-02-04 |
| 20160031983 | METHODS FOR TREATING CROHN'S DISEASE USING AN ANTI-IL23 ANTIBODY - The invention relates to products and methods for treating Crohn's disease. The products relate to antibodies that inhibit native human IL-23 while sparing IL-12. One example describes a Phase 1, randomized, double-blind, placebo-controlled, ascending multiple dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of an anti-IL-23 antibody (AMG 139) in healthy subjects and subjects with mild to severe Crohn's disease. | 2016-02-04 |
| 20160031984 | HUMANIZED ANTIBODIES THAT BIND LGR5 - Disclosed herein are humanized anti-LGR5 antibodies for the treatment of cancer. Antibodies disclosed herein may bind LGR5 without disrupting LGR5-RSPO1 binding or signaling, and may disrupt LGR5 signaling through Wnt that is independent of RSPO1. Also disclosed are heavy and light chain polypeptide sequences for the biding of LGR5, for example without disrupting LGR5-RSPO binding or signaling. | 2016-02-04 |
| 20160031985 | CHARGE-ENGINEERED ANTIBODIES OR COMPOSITIONS OF PENETRATION-ENHANCED TARGETING PROTEINS AND METHODS OF USE - The disclosure relates to charge-engineered antibodies and penetration-enhanced targeted proteins and their uses for therapeutic treatment or therapeutics delivery. | 2016-02-04 |
| 20160031986 | Therapeutic DLL4 Binding Proteins - DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis. | 2016-02-04 |
| 20160031987 | ANTI-EPHA2 ANTIBODY - The present invention provides an antibody which recognizes an epitope recognized by an antibody produced by a hybridoma SH348-1 (FERM BP-10836) or a hybridoma SH357-1 (FERM BP-10837), an antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, an antibody obtained by humanizing the antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, a pharmaceutical agent comprising the antibody as an active ingredient, etc. | 2016-02-04 |
| 20160031988 | MULTIVARIABLE ANTIGENS COMPLEXED WITH TARGETING HUMANIZED MONOCLONAL ANTIBODY - The present invention includes compositions and methods for designing, making and using modular recombinant antibodies or fragments thereof with one half of a cohesin-dockerin pair that permits the rapid assembly of multivariant antigen conjugates. | 2016-02-04 |
| 20160031989 | Methods for Promoting Reinnervation of Auditory Hair Cells - This invention relates to methods for promoting reinnervation of auditory hair cells, specifically, by inhibiting Repulsive Guidance Molecule a (RGMa), a repulsive axonal guidance molecule that is expressed in the cochlea, or its receptor, neogenin. | 2016-02-04 |
| 20160031990 | ANTAGONISTS OF PDL-1 AND PD-1 FOR THE TREATMENT OF HPV-NEGATIVE CANCERS - Provided herein are methods of treating HPV-negative tumors comprising administering an effective amount of an antagonist of the PDL-1/PD-1 interaction (e.g., an anti-PDL-1 or anti-PD-1 antibody antigen binding fragment thereof). | 2016-02-04 |
| 20160031991 | TARGETING VACCINES FOR VETERINARY USE - The present invention relates to therapeutic compounds, such as vaccines against avian diseases and in particular to DNA vaccines. The invention further relates to protein construct encoding homodimeric peptides, which peptides may be released from a DNA vaccine or used separately. Further described are pharmaceutical formulations, host cells and methods for producing the vaccines, as well as methods for the treatment or prevention of various diseases in animals, such as avians, such as cancers and infectious diseases. | 2016-02-04 |
| 20160031992 | ANTI-ALPHA V BETA 6 ANTIBODIES AND USES THEREOF - Humanized antibodies and antibody fragments thereof that bind to αvβ6 are disclosed. Also disclosed are methods of using these antibodies and antibody fragments to treat or prevent αvβ6-mediated diseases such as fibrosis and cancer. | 2016-02-04 |
| 20160031993 | COMPOSITIONS AND METHODS FOR INCREASING MUSCLE GROWTH - This disclosure is in the field of anti-Activin receptor IIB (ActRIIB) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse. | 2016-02-04 |
| 20160031994 | IL3Ralpha Antibody Conjugates And Uses Thereof - The present invention provides antibodies that bind to the IL-3 receptor alpha subunit alpha (Il3Rα) chain, and compositions comprising such antibodies. The present invention provides methods for inhibiting or reducing an IL3Rα-expressing cell population, the methods comprising contacting a population of IL3Rα-expressing cells (e.g., cancer cells and/or cancer stem cells) with an antibody that binds to IL3Rα. The present invention also provides antibody conjugates comprising an antibody that binds to an IL3Rα chain linked to a cytotoxic agent or anticellular agent and compositions comprising such conjugates. The present invention also provides methods for preventing, treating and/or managing a disorder associated with IL3Rα-expressing cells (e.g., a hematological cancer), the methods comprising administering to a subject in need thereof an antibody that binds to IL3Rα. | 2016-02-04 |
| 20160031995 | NOVEL ANTIBODIES FOR THE TREATMENT OF HIV - The present invention relates to novel isolated antibodies, or the derivatives or antigen binding fragments of same, capable of binding to CXCR4 but also of inducing conformational changed of the CXCR4 homodimers and able to inhibit HIV-1 primary isolate replication in PBMC. | 2016-02-04 |
| 20160031996 | ANTI IL-3R ALPHA AGENTS AND USES THEREOF - The present disclosure provides antibodies and antigen binding fragments thereof that bind to an epitope within an interleukin-3 receptor α. | 2016-02-04 |
| 20160031997 | METHODS AND COMPOSITIONS RELATING TO ANTI-CCR7 ANTIGEN BINDING PROTEINS - The present invention provides compositions and methods relating to antigen binding proteins against CCR7, including antibodies, nucleic acids, vectors, methods of making the antigen binding proteins, and methods of using the antigen binding proteins. | 2016-02-04 |
| 20160031998 | ANTIBODIES AGAINST G-CSFR AND USES THEREOF - The present disclosure provides proteins comprising antigen binding domains of antibodies that bind to human granulocyte-colony stimulating factor receptor. | 2016-02-04 |
| 20160031999 | IL-11R BINDING PROTEINS - The present disclosure provides proteins comprising antigen binding sites of antibodies that bind to interleukin-11 (IL-11) receptor alpha (IL-11Rα) and uses thereof, e.g., in therapy. | 2016-02-04 |
| 20160032000 | BLOOD-BRAIN-BARRIER DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 2016-02-04 |
| 20160032001 | ANTI-RANKL ANTIBODIES AND METHODS OF USE - The present invention provides anti-RANKL monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases. | 2016-02-04 |
| 20160032002 | Hybridoma Clones and Monoclonal Antibodies to CD9 - The present invention is directed to a monoclonal antibody that recognizes human CD9 in its native form. The invention is also directed to a hybridoma cell line that produces the monoclonal antibody, and exosome isolation kits using the antibody. | 2016-02-04 |
| 20160032003 | Therapeutic Use of Anti-CD22 Antibodies for Inducing Trogocytosis - Disclosed are methods and compositions of anti-B cell antibodies, preferably anti-CD22 antibodies, for diagnosis, prognosis and therapy of B-cell associated diseases, such as B-cell malignancies, autoimmune disease and immune dysfunction disease. In certain embodiments, trogocytosis induced by anti-B cell antibodies may determine antibody efficacy, disease responsiveness and prognosis of therapeutic intervention. In other embodiments, optimal dosages of therapeutic antibody may be selected by monitoring the degree of trogocytosis induced by anti-B cell antibodies. Other characteristics of anti-B-cell antibodies that may be monitored include inducing phosphorylation of CD22, CD79a and CD79b; inducing translocation of CD22, CD79a and CD79b to lipid rafts; inducing caspase-dependent apoptosis; increasing pLyn, pERKs and pJNKs; decreasing constitutively-active p38; or inducing mitochondrial membrane depolarization, generation of reactive oxygen species, upregulation of pro-apoptotic Bax and downregulation of anti-apoptotic Bcl-xl, Mcl-1 and Bcl-2. | 2016-02-04 |
| 20160032004 | Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity - The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 16 mg/kg, preferably 4, 6, 8, 9, 10, 12, or 16 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. | 2016-02-04 |
| 20160032005 | METHODS AND PHARMACEUTICALS COMPOSITIONS FOR TREATING BREAST CANCERS - The present invention relates to methods and pharmaceutical compositions for treating breast cancers. In particular, the present invention relates to a method for predicting the survival of a patient suffering from a breast cancer comprising i) determining the expression level of Vangl2 in a tumor sample obtained from the patient, ii) comparing the expression level determined at step i) with a predetermined reference value and iii) providing a poor prognosis when the expression level determined at step i) is higher than the predetermined reference value. The present invention also relates to a method for treating a patient suffering from a breast cancer comprising the steps consisting of i) predicting the survival of the patient according to claim | 2016-02-04 |
| 20160032006 | THERAPEUTIC AND DIAGNOSTIC TARGET FOR CANCER COMPRISING DLL3 BINDING REAGENTS - The present disclosure provides methods and compositions for treatment, screening, diagnosis and prognosis of cancer, such as lung cancer, pancreatic cancer and skin cancer, for monitoring the effectiveness of cancer, such as lung cancer, pancreatic cancer and skin cancer treatment, and for drug development. | 2016-02-04 |
| 20160032007 | Human Antibody Fragments Against Chondroitin Sulfate Proteoglycan 4 (CSPG4) - Human antibody fragments against chrondroitin sulfate proteoglycan 4 can be used to deliver cytotoxic agents to cells which express CSPG4. The agents can be diagnostic or therapeutic moieties. They may be linked by covalent or non-covalent linkages to the antibody fragments. They may be produced as a genetic fusion product or joined together synthetically, for example. When the human antibody fragments are internalized by the cells to which they bind, they can carry with them the attached agents. Thus toxic agents having intracellular targets have enhanced killing upon internalization. | 2016-02-04 |
| 20160032008 | Stable Compositions of High-Concentration Allotype-Selected Antibodies for Small-Volume Administration - Disclosed are methods, compositions and uses of high concentration antibody or immunoglobulin formulations for subcutaneous, intramuscular, transdermal or other local (regional) administration, in a volume of than 3, less than 2 or less than 1 ml. Preferably, the formulation contains a high concentration formulation (HCF) buffer comprising phosphate, citrate, polysorbate 80 and mannitol at a pH of about 5.2. The formulation more preferably comprises at least 100, 150, 200, 250 mg/ml or 300 mg/ml of antibody. The methods for preparing the high concentration formulation include ultrafiltration and diafiltration to concentrate the antibody and exchange the medium for HCF buffer. Other embodiments concern use of non-G1m1 (nG1m1) allotype antibodies, such as G1m3 and/or a nG1m1,2 antibodies. The nG1m1 antibodies show decreased immunogenicity compared to G1m1 antibodies. | 2016-02-04 |
| 20160032009 | HIGH AFFINITY ANTI-GD2 ANTIBODIES - In this application are described high affinity anti-GD2 antibody agents, and various methods and reagents related thereto, including for example for the detection, prevention, and/or therapeutical treatment of GD2-related diseases, in particular, neuroblastoma. | 2016-02-04 |
| 20160032010 | METHOD FOR PREPARING GLYCAN-HYDROLYZED ANTIBODY, AND HOMOGENEOUS GLYCOSYLATED ANTIBODY - The present invention is aimed to provide a method for preparing an acceptor that is N-glycan hydrolyzed antibody or a Fc fragment thereof used for producing antibody having a homogeneous N-glycan structure; a method for determining a combination of endoglycosidases for use in said preparation; and a method for measuring N-glycans linked to an antibody. The present invention is directed to a method for producing a N-glycan hydrolyzed antibody or Fc fragment thereof, comprising reacting the antibody or the Fc fragment thereof with several endoglycosidases; and a method for determining quantitative information of an objective N-glycan with a desired structure linked to an antibody or a Fc thereof, comprising a protease treatment step and a glycopeptide measurement step, etc. | 2016-02-04 |
| 20160032011 | HER3 SPECIFIC MONOCLONAL ANTIBODIES FOR DIAGNOSTIC AND THERAPEUTIC USE - Isolated or recombinant anti-HER3 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer. | 2016-02-04 |
| 20160032012 | ANTIBODIES CAPABLE OF SPECIFICALLY BINDING TWO EPITOPES ON TISSUE FACTOR PATHWAY INHIBITOR - The application discloses a combination of two monospecific TFPI antibodies, wherein one antibody is capable of specifically binding TFPI (1-181) and the other antibody is capable of specifically binding TFPI (182-276), as well as bispecific anti-TFPI antibodies derived from two such monospecific antibodies. Both the combination of the two monospecific antibodies and the bispecific antibody strongly enhance thrombin generation by neutralising full length TFPIα, even where the concentration of TFPI is abnormally elevated. | 2016-02-04 |
| 20160032013 | RON COMPOSITIONS AND METHODS OF USE THEREOF - This invention relates to RON compositions, in particular RON composition comprising a RON agonist, and methods of using the compositions for the treatment of diseases. The invention also relates to diagnosis of RON-associated or MSP-associated diseases. | 2016-02-04 |
| 20160032014 | HUMAN ANTIGEN BINDING PROTEINS THAT BIND TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 - The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inhibiting PCSK9 binding to LDLR and having increased pH sensitivity, improved binding affinity and/or increased in vivos half life. In embodiments, the antigen binding proteins specifically bind PCSK9 and have increased pH sensitivity, improved binding affinity and/or increased in vivos half life. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind PCSK9 Other embodiments provide nucleic acids encoding such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from hypercholesterolemia and related disorders or conditions. | 2016-02-04 |
| 20160032015 | Stabilized Formulations Containing Anti-PCSK9 Antibodies - The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months. | 2016-02-04 |
| 20160032016 | MOLECULES AND METHODS FOR TREATMENT OF DIABETES - Described are antibodies that specifically recognize and bind the epitope of glutamate decarboxylase (GAD65) that is bound by antibody b96.11, and anti-idiotypic antibodies that are capable of competing with GAD65 for binding with b96.11 and competitively inhibit such binding. These antibodies can be provided in the form of a pharmaceutical composition and can be used in methods for delaying the onset of Type 1 diabetes and for inhibiting insulitis and other diabetic symptoms. Also provided are methods for detecting a susceptibility to Type 1 diabetes in a subject and for detecting the presence of anti-idiotypic antibodies to GAD65. The method comprises contacting a specimen with an antibody of the invention. The method further comprises detecting binding of the molecule to the specimen. The absence (or relative absence) of binding is indicative of susceptibility to Type 1 diabetes and of the absence of anti-idiotypic antibodies. | 2016-02-04 |
| 20160032017 | ANTIBODIES SPECIFIC TO A NOVEL EPITOPE ON CEMX OF HUMAN MEMBRANE-BOUND IGE AND USES THEREOF IN TREATING IGE-MEDIATED DISEASES - The present disclosure relates to anti-IgE antibodies that bind to novel antigenic epitopes of the CsmX domain, e.g., SVPHPRCHCGAGRA (SEQ ID NO: 4) and the uses thereof in treating IgE-mediated diseases. | 2016-02-04 |
| 20160032018 | USE OF IGG1 IMMUNOGLOBULINS AND/OR LIGANDS OF THE CD32 RECEPTOR FOR TREATING INFLAMMATORY DISEASES AND INCIDENTS VIA THE MUCOSA - The present invention concerns the use of immunoglobulins of IgG | 2016-02-04 |
| 20160032019 | Antibody constructs for CDH19 and CD3 - The present invention provides to a bispecific antibody construct comprising a first human binding domain which binds to human CDH19 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct. | 2016-02-04 |
| 20160032020 | CELLULOSE ACETATE WITH A LOW DEGREE OF SUBSTITUTION - A cellulose acetate according to the present invention has a total degree of acetyl substitution of 0.4 to 1.1 and has a compositional distribution index (CDI) of 3.0 or less, where the CDI is specified by the formula: | 2016-02-04 |
| 20160032021 | METHOD OF PRODUCING REGENERATED CELLULOSE AND HEMICELLULOSE - A method of producing regenerated cellulose and hemicellulose from a fibre pulp which is prepared by using chemical cooking. Hemicellulose and, correspondingly, cellulose is separated from the pulp, in order to form separate fractions, by dissolving them in such a solvent or an aqueous solution of it, from which they are precipitated by adding water, after which the regenerated hemicellulose and cellulose can be recovered. Hemicellulose-containing pulp, which for example is used as raw material of paper, can be efficiently fractionated into polymeric hemicellulose-rich fractions and very pure cellulose fractions, such as regenerated cellulose fibre, various cellulose particles or cellulose films. | 2016-02-04 |
| 20160032022 | MICROPROCESSING FOR PREPARING A POLYCONDENSATE - The present invention relates to a process for preparing polydextrose by using a microdevice. It further relates to the use of a microdevice for the polycondesation reactions. | 2016-02-04 |
| 20160032023 | CONTINUOUS EMULSION POLYMERIZATION PROCESS AND INITIATION SYSTEM - In a continuous emulsion polymerization process, at least one monomer, an aqueous phase, and at least two different redox initiators are added to a continuous polymerization reactor comprising a first zone and a second zone. At least one redox initiator is added to the first zone and at least one redox initiator is added to the second zone. | 2016-02-04 |
| 20160032024 | Activating Agents for Hafnium-Based Metallocene Components - The present invention discloses an active metallocene catalyst system prepared with a hafnium-based metallocene catalyst system and an activating agent comprising an aluminoxane and a sterically hindered Lewis base. | 2016-02-04 |
| 20160032025 | LIGANDS FOR CATALYSTS - Catalyst systems and methods for making and using the same. A catalyst system can include a non-metallocene catalyst having the structure: wherein M is a group 4 element, each of R | 2016-02-04 |
| 20160032026 | CATALYST COMPONENTS FOR THE POLYMERIZATION OF OLEFINS - A solid catalyst component for the (co)polymerization of olefins CH | 2016-02-04 |
| 20160032027 | NOVEL BIMODAL RESINS HAVING GOOD FILM PROCESSABILITY - A bimodal polyethylene copolymer comprising a lower molecular weight (LMW) component and a higher molecular weight (HMW) component, the copolymer having a z-average molecular weight (M | 2016-02-04 |
| 20160032028 | POLYELECTROLYTE POLYMERS, THEIR MANUFACTURE AND USE - A method of forming a polyelectrolyte polymer by photopolymerizing a monomer having an ionic group covalently linked to a photocurable group. The ionic group can be borate and/or phosphonium ion. The polymer can be cross-linked as by diacrylate. | 2016-02-04 |
| 20160032029 | CROSSLINKING CONTROL IN HIGH IMPACT POLYSTYRENE MANUFACTURING PROCESS - The method includes providing a high impact polystyrene (HIPS) reaction system, wherein the HIPS reaction system has a devolitalizer downstream of a reactor and injecting a retarding agent into the HIPS reaction system prior to the devolitalizer. | 2016-02-04 |
| 20160032030 | POLYMERS FUNCTIONALIZED WITH NITROSO COMPOUNDS - A method for preparing a functionalized polymer, the method comprising the steps of: (i) polymerizing monomer with a coordination catalyst to form a reactive polymer; and (ii) reacting the reactive polymer with a nitroso compound. | 2016-02-04 |
| 20160032031 | PROPYLENE/BUTENE INTERPOLYMER PRODUCTION SYSTEM AND METHOD - The present disclosure provides a process. In an embodiment, the process includes producing a propylene-based polymer in a gas-phase polymerization reactor ( | 2016-02-04 |
| 20160032032 | PROCESS FOR THE PREPARATION OF PROPYLENE TERPOLYMERS AND TERPOLYMERS OBTAINED THEREBY - Propylene terpolymers are prepared by polymerizing propylene, ethylene and an alpha-olefin selected from the group of C | 2016-02-04 |
| 20160032033 | METHODS FOR PRODUCING ALPHA-OLEFIN POLYMER AND HYDROGENATED ALPHA-OLEFIN POLYMER - Provided is a method for producing an α-olefin polymer, comprising the step of polymerizing one or more kinds of α-olefins each having 3 to 30 carbon atoms with a polymerization catalyst obtained by using: (A) a metallocene compound; (B) an ionic compound capable of reacting with the metallocene compound to transform the compound into a cation; (C) an organometallic compound; and (D) one or more kinds of compounds selected from the group consisting of (d-1) an alcohol, (d-2) a phenol, and (d-3) an ether compound, the catalyst having a ratio between the component (A) and the component (D) of from 10:1 to 1:100 in terms of a molar ratio, and having a ratio of the component (D) to the component (C) of less than 1 in terms of a molar ratio. | 2016-02-04 |
| 20160032034 | HAFNOCENE CATALYZED POLYETHYLENE FILMS HAVING RAPID CLING DEVELOPMENT - Polyethylene films may include a polyethylene copolymer polymerized in the presence of a hafnium-based metallocene catalyst, wherein the polyethylene comprises a solubility distribution breadth index (SDBI) less than or equal to 23° C.; a melt index (12) less than 1.5; a flow index (121) of from about 16 to about 28; and a melt flow ratio (121/12) of from about 18 to about 23. The film has a cling value that is at least 60% of a cling value the film has at 48 hours after time zero, and wherein time zero is equal to less than 24 hours. | 2016-02-04 |
| 20160032035 | Ethylene-Based Polymers and Articles Made Therefrom - An ethylene-based polymer comprising about 80.0 to 99.0 wt. % of polymer units derived from ethylene and about 1.0 to about 20.0 wt. % of polymer units derived from one or more C | 2016-02-04 |
| 20160032036 | COPOLYMER AND HYDROPHILIC MATERIAL COMPOSED OF THE SAME - Provided are a cured product (for example, a film), in which the balance between hydrophilicity and abrasion resistance is superior, decrease in hydrophilicity by water is minimal, and the weather resistance is also superior, as well as a polymer and a polymer composition that can yield such a cured product. A polymer of the invention is a specific copolymer (i) having a sulfonic acid-containing group, an epoxy group, and a specific alkoxysilyl group in a molecule. | 2016-02-04 |
| 20160032037 | COPOLYMER, AQUEOUS INK, AND INK CARTRIDGE - A copolymer contains a structure unit represented by Chemical formula 1 and a structure unit represented by Chemical formula 2, | 2016-02-04 |
| 20160032038 | POLYMERIC IONIC SALT CATALYSTS AND METHODS OF PRODUCING THEREOF - Provided herein are polymeric ionic salt catalysts that are useful in the non-enzymatic saccharification processes. The catalysts described herein hydrolyze cellulosic materials to produce monosaccharides and/or disaccharides. Saccharification of lignocellulosic materials, such as biomass waste products of agriculture, forestry and waste treatment, are of great economic and environmental relevance. As part of biomass energy utilization, attempts have been made to obtain ethanol (bioethanol) by hydrolyzing cellulose or hemicellulose, which are major constituents of plants. | 2016-02-04 |
| 20160032039 | METHOD FOR PRODUCING CROSSLINKED FLUOROELASTOMER - A method for producing a cross-linked fluoroelastomer including cross-linking a fluoroelastomer with a cross-linking agent in an inert gas atmosphere in the presence of an initiator. | 2016-02-04 |
| 20160032040 | Acrylic Grafted Polyether Resins Based on Phenol Steric Acid and Coating Compositions Formed Therefrom - Coating compositions can be prepared from an acrylic grafted polyether resin, wherein the smallest difunctional hydroxyl phenyl segment used to form the acrylic grafted polyether resin has a molecular weight greater than about 500, and wherein the smallest difunctional hydroxyl phenyl segment used to form the acrylic grafted polyether resin does not comprise two or more non-impaired hydroxyl groups attached to two or more different five-membered or six-membered carbon atom rings in a segment having a molecular weight less than about 500. The acrylic grafted polyether resin can be prepared by reacting a dihydroxyl compound and/or a diamine compound with a phenol stearic acid compound to produce a diphenol, reacting the diphenol with a diglycidyl ether compound to form a polyether resin, and mixing the polyether resin with an ethylenically unsaturated monomer component in the presence of an initiator to form the acrylic grafted polyether resin. | 2016-02-04 |
| 20160032041 | COPOLYMERS MADE WITH ALLYL-TERMINATED POLYOLEFINS AND UNSATURATED ACIDIC REAGENTS, DISPERSANTS USING SAME, AND METHODS OF MAKING SAME - Copolymers made with allyl-terminated polyolefins and unsaturated acidic reactants, dispersants using same, and methods of making same are provided. Under one aspect, a copolymer of an unsaturated acidic reactant and high molecular weight polyolefin, wherein the polyolefin comprises an allyl-terminated polymeric product, is provided. The allyl-terminated polymeric product is formed, e.g., by forming a quasi-living tert-halide terminated polyolefin under suitable quasi-living conditions, and contacting the tert-halide terminated polyolefin with an allylsilane compound and a Lewis acid. In some embodiments, the allylsilane compound includes allyltrimethylsilane. | 2016-02-04 |
| 20160032042 | Process for Producing Flexible Polyurethane Foam Using Natural Oil Polyols - A composition and process useful to make flexible polyurethane foams and in particular flexible molded polyurethane foams is disclosed. The usage of dipolar aprotic liquids such as DMSO, DMI, sulfolane, N-methyl-acetoacetamide, N, N-dimethylacetoacetamide as well as glycols containing hydroxyl numbers OH#≦1100 as cell opening aides for 2-cyanoacetamide or other similar molecules containing active methylene or methine groups to make a polyurethane foam is also disclosed. The advantage of using cell opener aids results in a) no foam shrinkage; b) lower use levels of cell opener; c) foam performance reproducibility d) optimum physical properties. In addition, combining the acid blocked amine catalyst together with the cell opener and the cell opener aid results in a less corrosive mixture as well as provides a method that does not require mechanical crushing for cell opening. | 2016-02-04 |
| 20160032043 | BISPHENOL POLYMER PRECURSOR REPLACEMENTS - Use of biologically-derived polyphenols for the preparation of epoxy resins is described. Examples of biologically-derived polyphenols include resveratrol, genistein, daidzein, and polyphenols synthesized from tyrosine. Because the epoxy resins are prepared from biologically-derived materials, they provide epoxy resins that will degrade into biologically harmless materials. The epoxy resins can be used to provide coating compositions. | 2016-02-04 |
| 20160032044 | Process For Producing Articles Formed From Polylactic Acid and Articles Made Therefrom - PLA polymers that can be expanded into microporous articles having a node and fibril microstructure are provided. The fibrils contain PLA polymer chains oriented with the fibril axis. Additionally, the PLA polymers have an inherent viscosity greater than about 3.8 dL/g and a calculated molecular weight greater than about 150,000 g/mol. The PLA polymer article may be formed by bulk polymerization where the PLA bulk polymer is made into a preform that is subsequently expanded at temperatures above the glass transition temperature and below the melting point of the PLA polymer. In an alternate embodiment, a PLA polymer powder is lubricated, the lubricated polymer is subjected to pressure and compression to form a preform, and the preform is expanded to form a microporous article. Both the preform and the microporous article are formed at temperatures above the glass transition temperature and below the melting point of the PLA polymer. | 2016-02-04 |
| 20160032045 | USE OF POLYESTERS HAVING INHERENT FLAME PROTECTION IN ADHESIVES AND SEALANTS - The present invention relates to the use of polyesters with inherent flame retardancy as or in adhesives, sealants and coatings, to polyesters with inherent flame retardancy and to processes for production thereof. | 2016-02-04 |
| 20160032046 | POLYCARBONATE MANUFACTURING METHOD AND POLYCARBONATE - The present invention relates to a method of producing polycarbonate containing following step (a) and step (b), (a) a step of reacting a specific fluorine-containing carbonate (Compound (1), etc.) and an aromatic dihydroxy compound in the presence of a condensation catalyst, to obtain a prepolymer, and (b) a step of heating the prepolymer at a temperature which is lower than a melting temperature of the prepolymer and performing solid phase polymerization on the prepolymer while a fluorine-containing alcohol that is produced as a by-product is discharged out of a system, to obtain a polycarbonate. | 2016-02-04 |
| 20160032047 | Peg-based adhesive phenylic derivatives and methods of synthesis and use - The invention provides compositions that use phenylic derivatives to provide adhesive properties. Selection of phenylic derivatives with linkers or linking groups, and the linkages between the linkers or linking groups with polyalkylene oxides, provided herein may be configured to control curing time, biodegradation and/or swelling. | 2016-02-04 |
| 20160032048 | Bisphenol-A Free Polyether Resins Based on Phenol Stearic Acid and Coating Compositions Formed Therefrom - Coating compositions can be prepared from a polyether resin, wherein the smallest difunctional hydroxyl phenyl segment used to form the polyether resin has a molecular weight greater than about 500, and wherein the smallest difunctional hydroxyl phenyl segment used to form the polyether resin does not comprise two or more non-impaired hydroxyl groups attached to two or more different five-membered or six-membered carbon atom rings in a segment having a molecular weight less than about 500. The polyether resin can be prepared by reacting a dihydroxyl compound and/or a diamine compound with a phenol stearic acid compound to produce a diphenol, and reacting the diphenol with a diglycidyl ether compound to form the polyether resin. | 2016-02-04 |
| 20160032049 | BRANCHED POLYMERS - The present invention is directed to branched reactive water-soluble polymers comprising at least two polymer arms, such as poly(ethylene glycol), attached to a central aliphatic hydrocarbon core molecule through heteroatom linkages. The branched polymers bear at least one functional group for reacting with a biologically active agent to form a biologically active conjugate. The functional group of the branched polymer can be directly attached to the aliphatic hydrocarbon core or via an intervening linkage, such as a heteroatom, -alkylene-, —O-alkylene-O—, -alkylene-O-alkylene-, -aryl-O—, -D-aryl-, (—O-alkylene-) | 2016-02-04 |
| 20160032050 | REACTOR HAVING A VERTICAL CONDENSATION TUBE AND METHOD FOR THE POLYMERIZATION OF POLYAMIDES IN SUCH A REACTOR - The invention relates to a reactor in the form of a VK tube (VK: simplified continuous), for the polymerisation of polyamides, the reactor being subdivided into an upper and lower reactor region, which are controllable independently of each other. Likewise, the invention relates to a method for the production of polyamides in which such a reactor is used. | 2016-02-04 |
| 20160032051 | Copolymerized Polyamide Resin, Method for Preparing the Same and Article Comprising the Same - A copolymerized polyamide resin includes a polymer of a monomer mixture comprising a dicarboxylic acid component and a diamine component including about 4 mol % to about 20 mol % of an alicyclic diamine represented by the Formula 1, wherein the polyamide resin has a melting temperature (Tm) from about 280 to about 330° C. and a crystallization temperature (Tc) from about 250 to about 300° C.: | 2016-02-04 |
| 20160032052 | PROCESS FOR MANUFACTURING POLYAMIDE - In one or a plurality of embodiments, a process for manufacturing polyamide, with a reduced use of an amide-based solvent in synthesis, is provided. In one or a plurality of embodiments, provided is a process for manufacturing polyamide, including steps (a) to (c): (a) dissolving diacid dichloride in a non-amide-based organic solvent; (b) adding diamine to a solution obtained in the step (a) and reacting the diacid dichloride with the diamine so as to generate polyamide; and (c) adding a trapping reagent capable of trapping hydrochloric acid, at any time at least before the step (b), at the same time of starting the step (b), or during the step (b). | 2016-02-04 |
